Samaritan acquires rights to Abiogen’s cancer drug

Abioklad is used for the treatment of cancer malignancy-associated hypercalcemia (high blood calcium), the inhibition of osteolysis (degeneration of bone tissue), and the decrease of bone pain associated with cancer. Discovered by Abiogen Pharma, Abioklad is a bisphosphonate that binds to calcium and inhibits osteoclastic bone resorption, crystal formation, and dissolution, resulting in a reduction of bone turnover.

Janet Greeson, chairman, president, and CEO of Samaritan Pharmaceuticals, said: “Commercializing branded approved prescription products in Greece and Eastern Europe is a priority within Samaritan’s strategy to generate enough revenue to cover our burn rate and become cash-flow positive. We feel we can get Abioklad to market pretty quickly and appreciate the confidence the Abiogen team has in Samaritan.”